Skip to Main Content

Author Details

Levi A Garraway
Broad Institute of Harvard and MIT
1991
241
125
PMIDPaper TitleJournal TitlePublished Year
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35482859Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.Science2022
35537413An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.Cancer Cell2022
35190823Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.Clin Cancer Res2022
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35537413An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.Cancer Cell2022
35482859Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.Science2022
35190823Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.Clin Cancer Res2022
34188191Making cancer research more inclusive.Nat Rev Cancer2021
34188191Making cancer research more inclusive.Nat Rev Cancer2021
33597266Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.Sci Transl Med2021
33597266Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.Sci Transl Med2021
32404308The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer Discov2020
32404308The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer Discov2020
31712683Synthetic lethality as an engine for cancer drug target discovery.Nat Rev Drug Discov2020
32686686Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.Nat Commun2020
32572264A single-cell landscape of high-grade serous ovarian cancer.Nat Med2020
32561875Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2020
31712683Synthetic lethality as an engine for cancer drug target discovery.Nat Rev Drug Discov2020
32686686Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.Nat Commun2020
32572264A single-cell landscape of high-grade serous ovarian cancer.Nat Med2020
32561875Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2020
30559381Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature2019
31792460Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2019
31554815Metabolomic adaptations and correlates of survival to immune checkpoint blockade.Nat Commun2019
30559381Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature2019
30819666A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.Cancer Res2019
31164371Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.Clin Cancer Res2019
31068703The landscape of cancer cell line metabolism.Nat Med2019
31068700Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
31462500Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.Mol Cancer Res2019
30709805MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant Melanomas.Cancer Discov2019
31792460Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med2019
31554815Metabolomic adaptations and correlates of survival to immune checkpoint blockade.Nat Commun2019
31462500Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.Mol Cancer Res2019
31068703The landscape of cancer cell line metabolism.Nat Med2019
31068700Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019
30709805MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant Melanomas.Cancer Discov2019
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
31164371Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.Clin Cancer Res2019
30819666A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.Cancer Res2019
29144510Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers.Genet Med2018
30388455A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.Cell2018
29903880Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.Cancer Discov2018
30567725Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Blood Adv2018
30133189Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience.Mol Genet Genomic Med2018
29900052TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor <i>CD274</i> (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.Oncoimmunology2018
30078722Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.Mol Cell2018
29628419Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.Cell Metab2018
  • 1 - 50 of 482

Recommended Authors

Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 3
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 10
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 41
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 12
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 54
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 25
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 3
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 18
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 9
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 25
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 53
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 44
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 21
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 20
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 16
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 20
Peter Van Loo
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 20
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 4
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 8
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 60
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 28
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 9
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 11
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 12
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 51
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 2
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 25
Yardena Samuels
Weizmann Institute of Science
Career Start Year 1998
Number of shared co-authors 24
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 26
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 24

Collaborators

Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 59
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 50
Matthew Meyerson
Broad Institute
Co-authored papers 48
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 38
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 35
Nikhil Wagle
Dana-Farber Cancer Institute
Co-authored papers 32
Eric S Lander
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 30
Mark A Rubin
University of Bern
Co-authored papers 27
William R Sellers
Co-authored papers 27
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 26
Gregory V Kryukov
Co-authored papers 25
Scott L Carter
Co-authored papers 23
Michael S Lawrence
Co-authored papers 23
Rameen Beroukhim
Co-authored papers 21
Laura E MacConaill
Co-authored papers 20
David E Root
Broad Institute of Harvard and MIT
Co-authored papers 20
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 19
Wendy Winckler
Co-authored papers 19
Carrie Sougnez
The Broad Institute of Harvard and MIT
Co-authored papers 19
Kristian Cibulskis
Co-authored papers 19
Nicolas Stransky
Co-authored papers 18
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 18
Jordi Barretina
Co-authored papers 17
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 15
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 15
Francesca Demichelis
University of Trento
Co-authored papers 15
Andrey Sivachenko
Cystic Fibrosis Foundation
Co-authored papers 14
Robert C Onofrio
The Broad Institute of Harvard and MIT
Co-authored papers 13
Mahmoud Ghandi
Co-authored papers 13
Alex H Ramos
Co-authored papers 12
Release 1.2